Publikationen 2014

Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G.
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma.
Clin Genitourin Cancer. 2014 Apr;12(2):130-7.
doi: 10.1016/j.clgc.2013.09.002. Epub 2013 Sep 28. PubMed PMID: 24220220; PubMed Central PMCID: PMC4142680.

Albers P.
Epidemiological studies are important to trigger health care decisions.
Eur Urol. 2014 Jun;65(6):1107-8.
doi: 10.1016/j.eururo.2013.11.032. Epub 2013 Nov 28. PubMed PMID: 24314828.

Albers P.
Hodenkarzinom - Organerhaltende OP ohne Ischämie ist vielversprechend.
Aktuelle Urol. 2014 Sep;45(5):350-2.
doi: 10.1055/s-0034-1393915. Epub 2014 Oct 2. German. PubMed PMID: 25275684.

Albers P.
Poor-prognosis Germ Cell Tumours: Room for Improvement.
Eur Urol. 2014 Nov 20. pii: S0302-2838(14)01183-X.
doi: 10.1016/j.eururo.2014.11.009. [Epub ahead of print] PubMed PMID: 25465972.

Albers P, Heidenreich A.
Radikale Zystoprostatektomie und pelvine Lymphadenektomie.
Aktuelle Urol. 2014 Nov;45(6):490-8.
doi: 10.1055/s-0034-1395577. Epub 2014 Dec 16. German. PubMed PMID: 25514780.

Arsov C, Jankowiak F, Hiester A, Rabenalt R, Quentin M, Schimmöller L, Blondin D, Antoch G, Albers P.
Prognostic value of a cell-cycle progression score in men with prostate cancer managed with active surveillance after MRI-guided prostate biopsy--a pilot study.
Anticancer Res. 2014 May;34(5):2459-66.
PubMed PMID: 24778061.

Babaian KN, Skarecky D, Liss MA, Osann K, Lusch A, Ahlering TE.
A comparative analysis of complications after robot-assisted radical prostatectomy for men aged ≤69 and ≥70 years.
J Endourol. 2014 Dec;28(12):1435-8.
doi: 10.1089/end.2014.0234. PubMed PMID: 25211698.

Berger LA, Bokemeyer C, Lorch A, Hentrich M, Kopp HG, Gauler TC, Beyer J, de Wit M, Mayer F, Boehlke I, Oing C, Honecker F, Oechsle K.
First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG).
J Cancer Res Clin Oncol. 2014 Jul;140(7):1211-20.
doi: 10.1007/s00432-014-1661-z. Epub 2014 Apr 3. PubMed PMID: 24696231.

Boccon-Gibod L, Albers P, Morote J, van Poppel H, de la Rosette J, Villers A, Malmberg A, Neijber A, Montorsi F.
Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
Eur Urol. 2014 Oct;66(4):655-63.
doi: 10.1016/j.eururo.2014.05.037. Epub 2014 Jun 18. PubMed PMID: 24954791.

Decoene J, Winter C, Albers P.
False-positive fluorodeoxyglucose positron emission tomography results after chemotherapy in patients with metastatic seminoma.
Urol Oncol. 2015 Jan;33(1):23.e15-21.
doi: 10.1016/j.urolonc.2014.09.019. Epub 2014 Nov 4. PubMed PMID: 25454484.

Del Junco M, Okhunov Z, Yoon R, Khanipour R, Juncal S, Abedi G, Lusch A, Landman J.
Development and initial porcine and cadaver experience with three-dimensional printing of endoscopic and laparoscopic equipment.
J Endourol. 2015 Jan;29(1):58-62.
doi: 10.1089/end.2014.0280. PubMed PMID: 24983138; PubMed Central PMCID: PMC4287134.

Esch L, Schulz WA, Albers P.
Sequential treatment with taxanes and novel anti-androgenic compounds in castration-resistant prostate cancer.
Oncol Res Treat. 2014;37(9):492-8.
doi: 10.1159/000365530. Epub 2014 Jul 11. PubMed PMID: 25231690.

Friedersdorff F, Roller C, Manus P, Cash H, Stier K, Schmidt D, Budde K, Kemkensteffen C, Busch J, Fuller TF, Giessing M.
Fate of finally transplanted deceased donor kidneys initially rejected at other kidney transplantation centers.
Urol Int. 2014;93(4):474-81.
doi: 10.1159/000360302. Epub 2014 Aug 22. PubMed PMID: 25171397.

Greife A, Jankowiak S, Steinbring J, Nikpour P, Niegisch G, Hoffmann MJ, Schulz WA.
Canonical Notch signalling is inactive in urothelial carcinoma.
BMC Cancer. 2014 Aug 29;14:628.
doi: 10.1186/1471-2407-14-628. PubMed PMID: 25167871; PubMed Central PMCID: PMC4242495.

Goebell PJ, Kamat AM, Sylvester RJ, Black P, Droller M, Godoy G, Hudson MA, Junker K, Kassouf W, Knowles MA, Schulz WA, Seiler R, Schmitz-Dräger BJ.
Assessing the quality of studies on the diagnostic accuracy of tumor markers.
Urol Oncol. 2014 Oct;32(7):1051-60.
doi: 10.1016/j.urolonc.2013.10.003. Epub 2014 Aug 20. PubMed PMID: 25159014.

Knievel J, Schulz WA, Greife A, Hader C, Lübke T, Schmitz I, Albers P, Niegisch G.
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer.
Int J Mol Sci. 2014 Nov 7;15(11):20500-17.
doi: 10.3390/ijms151120500. PubMed PMID: 25387078; PubMed Central PMCID: PMC4264180.

Krege S, Rexer H, vom Dorp F, de Geeter P, Klotz T, Retz M, Heidenreich A, Kühn M, Kamradt J, Feyerabend S, Wülfing C, Zastrow S, Albers P, Hakenberg O, Roigas J, Fenner M, Heinzer H, Schrader M.
Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).
BJU Int. 2014 Mar;113(3):429-36.
doi: 10.1111/bju.12437. PubMed PMID: 24053564.

Lavery HJ, Stensland KD, Niegisch G, Albers P, Droller MJ.
Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate.
J Urol. 2014 Apr;191(4):898-906.
doi: 10.1016/j.juro.2013.10.142. Epub 2013 Dec 1. Review. PubMed PMID: 24300483.

Lehmann M, Hoffmann MJ, Koch A, Ulrich SM, Schulz WA, Niegisch G.
Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment.
J Exp Clin Cancer Res. 2014 Jul 10;33:59.
doi: 10.1186/s13046-014-0059-8. PubMed PMID: 25011684; PubMed Central PMCID: PMC4230422.

Liss MA, Gordon A, Morales B, Osann K, Skarecky D, Lusch A, Zaldivar F, Ahlering TE.
Urinary nerve growth factor as an oncologic biomarker for prostate cancer aggressiveness.
Urol Oncol. 2014 Jul;32(5):714-9.
doi: 10.1016/j.urolonc.2014.01.018. Epub 2014 Apr 29. PubMed PMID: 24794250.

Lorch A.
A practice-changing step forward in germ-cell cancer?
Lancet Oncol. 2014 Dec;15(13):1409-10.
doi: 10.1016/S1470-2045(14)71103-9. Epub 2014 Nov 13. PubMed PMID: 25456352.

Lusch A, Bucur PL, Menhadji AD, Okhunov Z, Liss MA, Perez-Lanzac A, McDougall EM, Landman J.
Evaluation of the impact of three-dimensional vision on laparoscopic performance.
J Endourol. 2014 Feb;28(2):261-6.
doi: 10.1089/end.2013.0344. Epub 2014 Jan 10. PubMed PMID: 24059674.

Lusch A, Leary R, Heidari E, Liss MA, Okhunov Z, Perez-Lanzac De Lorca A, Huang J, Wikenheiser J, Landman J.
Intrarenal and extrarenal autonomic nervous system redefined.
J Urol. 2014 Apr;191(4):1060-5.
doi: 10.1016/j.juro.2013.11.108. Epub 2013 Dec 11. PubMed PMID: 24333240.

Lusch A, Okhunov Z, Del Junco M, Yoon R, Khanipour R, Menhadji A, Landman J.
Comparison of Optics and Performance of Single Channel and a Novel Dual-channel Fiberoptic Ureteroscope.
Urology. 2015 Jan;85(1):268-72.
doi: 10.1016/j.urology.2014.09.032. PubMed PMID: 25530400.

Lusch A, Zaum M, Winter C, Albers P.
[Management of complications after residual tumor resection for metastatic testicular cancer].
Urologe A. 2014 Jul;53(7):991-5.
doi: 10.1007/s00120-014-3502-8. German. PubMed PMID: 25023235.

Miller K, Albers P, Eichenauer R, Geiges G, Grimm MO, König F, Mickisch G, Pfister D, Schwentner C, Suttmann H, Zastrow S.
[Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring].
Urologe A. 2014 May;53(5):710-4.
doi: 10.1007/s00120-014-3491-7. Review. German. PubMed PMID: 24806804.

Niegisch G, Albers P, Rabenalt R.
Perioperative complications and oncological safety of robot-assisted (RARC) vs. open radical cystectomy (ORC).
Urol Oncol. 2014 Oct;32(7):966-74.
doi: 10.1016/j.urolonc.2014.03.023. Epub 2014 Jul 10. PubMed PMID: 25017695.

Nikpour M, Emadi-Baygi M, Fischer U, Niegisch G, Schulz WA, Nikpour P.
MTDH/AEG-1 contributes to central features of the neoplastic phenotype in bladder cancer.
Urol Oncol. 2014 Jul;32(5):670-7.
doi: 10.1016/j.urolonc.2013.11.005. Epub 2014 Feb 2. PubMed PMID: 24495449.

Oing C, Lorch A, Bokemeyer C, Honecker F, Beyer J, Berger LA, Oechsle K.
First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database.
J Cancer Res Clin Oncol. 2014 Nov 14.
[Epub ahead of print] PubMed PMID: 25395217.

Okhunov Z, del Junco M, Yoon R, Labadie K, Lusch A, Ordon M.
In vitro evaluation of LithAssist: a novel combined holmium laser and suction device.
J Endourol. 2014 Aug;28(8):980-4.
doi: 10.1089/end.2014.0111. Epub 2014 May 8. PubMed PMID: 24707884.

Okhunov Z, Juncal S, Ordon M, George AK, Lusch A, Del Junco M, Nguyentat M, Lobko II, Kavoussi L, Landman J.
Comparison of Outcomes in Patients Undergoing Percutaneous Renal Cryoablation With Sedation vs General Anesthesia.
Urology. 2015 Jan;85(1):130-4.
doi: 10.1016/j.urology.2014.09.013. Epub 2014 Nov 14. PubMed PMID: 25440762.

Oldenburg J, Aparicio J, Beyer J, Cohn-Cedermark G, Cullen M, Gilligan T, De Giorgi U, De Santis M, de Wit R, Fosså SD, Germà-Lluch JR, Gillessen S, Haugnes HS, Honecker F, Horwich A, Lorch A, Ondruš D, Rosti G, Stephenson AJ, Tandstad T; On behalf of: SWENOTECA (Swedish Norwegian Testicular Cancer group), the Italian Germ Cell Cancer Group (IGG), Spanish Germ Cell Cancer Group (SGCCG).
Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer.
Ann Oncol. 2014 Nov 6.
pii: mdu514. [Epub ahead of print] Review. PubMed PMID: 25378299.

Pond GR, Agarwal N, Bellmunt J, Choueiri TK, Qu A, Fougeray R, Vaughn D, James ND, Salhi Y, Albers P, Niegisch G, Galsky MD, Wong YN, Ko YJ, Stadler WM, O'Donnell PH, Sridhar SS, Vogelzang NJ, Necchi A, Di Lorenzo G, Sternberg CN, Mehta A, Sonpavde G.
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma.
BJU Int. 2014 May;113(5b):E137-43.
doi: 10.1111/bju.12564. PubMed PMID: 24219029.

Pond GR, Bellmunt J, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Sonpavde G.
Impact of the number of prior lines of therapy and prior perioperative chemotherapy in patients receiving salvage therapy for advanced urothelial carcinoma: implications for trial design.
Clin Genitourin Cancer. 2015 Feb;13(1):71-9.
doi: 10.1016/j.clgc.2014.06.004. Epub 2014 Jun 9. PubMed PMID: 24993933.

Quentin M, Blondin D, Arsov C, Schimmöller L, Hiester A, Godehardt E, Albers P, Antoch G, Rabenalt R.
Prospective evaluation of magnetic resonance imaging guided in-bore prostate biopsy versus systematic transrectal ultrasound guided prostate biopsy in biopsy naïve men with elevated prostate specific antigen.
J Urol. 2014 Nov;192(5):1374-9.
doi: 10.1016/j.juro.2014.05.090. Epub 2014 May 24. PubMed PMID: 24866597.

Quentin M, Pentang G, Schimmöller L, Kott O, Müller-Lutz A, Blondin D, Arsov C, Hiester A, Rabenalt R, Wittsack HJ.
Feasibility of diffusional kurtosis tensor imaging in prostate MRI for the assessment of prostate cancer: preliminary results.
Magn Reson Imaging. 2014 Sep;32(7):880-5.
doi: 10.1016/j.mri.2014.04.005. Epub 2014 Apr 21. PubMed PMID: 24848289.

Quentin M, Schimmöller L, Arsov C, Rabenalt R, Antoch G, Albers P, Blondin D.
Increased signal intensity of prostate lesions on high b-value diffusion-weighted images as a predictive sign of malignancy.
Eur Radiol. 2014 Jan;24(1):209-13.
doi: 10.1007/s00330-013-2999-3. Epub 2013 Aug 31. PubMed PMID: 23995881.

Ribarska T, Goering W, Droop J, Bastian KM, Ingenwerth M, Schulz WA.
Deregulation of an imprinted gene network in prostate cancer.
Epigenetics. 2014 May;9(5):704-17.
doi: 10.4161/epi.28006. Epub 2014 Feb 10. PubMed PMID: 24513574; PubMed Central PMCID: PMC4063830.

Rosik L, Niegisch G, Fischer U, Jung M, Schulz WA, Hoffmann MJ.
Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
Cancer Biol Ther. 2014 Jun 1;15(6):742-57.
doi: 10.4161/cbt.28469. Epub 2014 Mar 11. PubMed PMID: 24618845; PubMed Central PMCID: PMC4049790.

Schimmöller L, Quentin M, Arsov C, Hiester A, Buchbender C, Rabenalt R, Albers P, Antoch G, Blondin D.
MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy.
Eur Radiol. 2014 Oct;24(10):2582-9.
doi: 10.1007/s00330-014-3276-9. Epub 2014 Jun 28. PubMed PMID: 24972954.

Schimmöller L, Quentin M, Arsov C, Hiester A, Kröpil P, Rabenalt R, Albers P, Antoch G, Blondin D.
Predictive power of the ESUR scoring system for prostate cancer diagnosis verified with targeted MR-guided in-bore biopsy.
Eur J Radiol. 2014 Dec;83(12):2103-8.
doi: 10.1016/j.ejrad.2014.08.006. Epub 2014 Aug 30. PubMed PMID: 25241051.

Schulz WA.
Integrating epigenetics.
Biol Chem. 2014 Nov 1;395(11):1263-4.
doi: 10.1515/hsz-2014-0248. PubMed PMID: 25229415.

Sonpavde G, Bellmunt J, Rosenberg JE, Regazzi AM, Bajorin DF, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Pond GR.
Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma.
Clin Genitourin Cancer. 2014 Dec;12(6):395-8.
doi: 10.1016/j.clgc.2014.03.016. Epub 2014 Jun 10. PubMed PMID: 25035282.

Sonpavde G, Pond GR, Rosenberg JE, Bajorin DF, Regazzi AM, Choueiri TK, Qu AQ, Niegisch G, Albers P, Necchi A, Di Lorenzo G, Fougeray R, Dreicer R, Chen YH, Wong YN, Sridhar SS, Ko YJ, Milowsky MI, Galsky MD, Bellmunt J.
Complete Response as an Intermediate End Point in Patients Receiving Salvage Systemic Therapy for Urothelial Carcinoma.
Clin Genitourin Cancer. 2014 Oct 2.
pii: S1558-7673(14)00211-0. doi: 10.1016/j.clgc.2014.09.004. [Epub ahead of print] PubMed PMID: 25458370.

Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Théodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R; European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group; Groupe d'Etude des Tumeurs Urogénitales; National Cancer Research Institute Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; German Association of Urologic Oncology (AUO).
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Lancet Oncol. 2015 Jan;16(1):76-86.
doi: 10.1016/S1470-2045(14)71160-X. Epub 2014 Dec 11. PubMed PMID: 25498218.

Weilandt M, Koch A, Rieder H, Deenen R, Schwender H, Niegisch G, Schulz WA.
Target genes of recurrent chromosomal amplification and deletion in urothelial carcinoma.
Cancer Genomics Proteomics. 2014 May-Jun;11(3):141-53.
PubMed PMID: 24969694.

Werminghaus P, Haase M, Hornsby PJ, Schinner S, Schott M, Malendowicz LK, Lammers BJ, Goretzki PE, Müller-Mattheis V, Markus Giessing, Willenberg HS.
Hedgehog-signaling is upregulated in non-producing human adrenal adenomas and antagonism of hedgehog-signaling inhibits proliferation of NCI-H295R cells and an immortalized primary human adrenal cell line.
J Steroid Biochem Mol Biol. 2014 Jan;139:7-15.
doi: 10.1016/j.jsbmb.2013.09.007. Epub 2013 Sep 21. PubMed PMID: 24063979.

Zengerling F, Hartmann M, Heidenreich A, Krege S, Albers P, Karl A, Weissbach L, Wagner W, Bedke J, Retz M, Schmelz HU, Kliesch S, Kuczyk M, Winter E, Pottek T, Dieckmann KP, Schrader AJ, Schrader M; GTCSG (German Testicular Cancer Study Group).
German second-opinion network for testicular cancer: sealing the leaky pipe between evidence and clinical practice.
Oncol Rep. 2014 Jun;31(6):2477-81.
doi: 10.3892/or.2014.3153. Epub 2014 Apr 24. PubMed PMID: 24788853; PubMed Central PMCID: PMC4055348.

MediathekInformation und Wissen
LageplanSo finden Sie uns